KMT2A and acute leukemia: MLL1 inhibitors have been shown to be effective and safe in treating acute leukemia, and according to our research, it is possible that they could also be used to promote syncytialization, consequently offering the potential to improve the outcomes of various syncytialization dysregulation-associated diseases.